Latest Conference Articles

Response rates to enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors were the highest numerically observed for any regimen, according to findings from study EV-201 presented at the 2021 American Society of Clinical Oncology Genitourinary Cancer Symposium.

Eleni Efstathiou, MD, PhD, provides background on the ARAMIS trial of darolutamide compared with placebo as treatment of patients with nonmetastatic castration-resistant prostate cancer.

Nivolumab in combination with cabozantinib continues to demonstrate superior efficacy over sunitinib monotherapy in the frontline treatment of patients with advanced renal cell carcinoma, according to extended follow-up data from the phase 3 CheckMate 9ER trial.

A novel prostate-specific membrane antigen–targeted radiopharmaceutical for positron emission tomography known as 18F-DCFPyL, may help to identify occult prostate cancer and more accurately characterize disease burden, according to a subanalysis of the OSPREY trial presented during the 2021 Genitourinary Cancers Symposium.

In patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), crossover from placebo to darolutamide (Nubeqa) appeared have minimal impact on the overall survival (OS) benefit observed with the androgen receptor inhibitor in the pivotal phase 3 ARAMIS trial.

The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.

Nivolumab plus cabozantinibreportedly improved health-related quality of life for patients with advanced renal cell carcinoma when compared to treatment with sunitinib.

Results from the phase 3, randomized REACH3 trial further demonstrated the benefit of ruxolitinib over BAT in rates for failure-free survival, symptom improvement, and duration of response.

Data presented during the 2021 Transplantation and Cellular Therapy Meeting showed that treatment with Orca-T, achieved a significant reduction in cases of graft-versus-host disease and other impressive outcomes.

A retrospective study has suggested that immunotherapy may have a great survival benefit in the frontline setting for patients with metastatic non–clear cell renal cell carcinoma (RCC) than select targeted therapies.

In the phase 3 ACIS study, the addition of apalutamide to abiraterone acetate lead to a reduction in the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.

A subgroup analysis from the phase 3 JAVELIN Bladder 100 trial demonstrated that Japanese patients with advanced urothelial cancer whose disease did not progress on frontline chemotherapy benefited from the addition of avelumab to best supportive care in the first-line maintenance setting.

Response rates in patients with metastatic urothelial carcinoma were boosted when the novel PI3K-y inhibitor eganelisib was added to nivolumab, according to recent research presented during the American Society of Clinical Oncology 2021 Genitourinary Cancers Symposium.

In patients with clear cell renal cell carcinoma who had been treated with an immune checkpoint inhibitor in prior lines of therapy, lenvatinib in combination with everolimus was found to be safe and effective.

Targeted radioimmunotherapy to the marrow with apamistamab conditioning therapy led to high rates of allogeneic hematopoietic stem cell transplant in patients with active, relapsed, or refractory acute myeloid leukemia, according to interim data from the phase 3 SIERRA trial.

Haris Ali, MD, discusses the results of a study evaluating peri-transplant ruxolitinib in patients with myelofibrosis.

Results from 2 phase 3 clinical trials showed that use of the investigational gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients under the age of 18 years with transfusion-dependent beta-thalassemia.

Five-year follow-up data from the phase 3 CLTR0310-301 clinical trial shows continued OS benefit with the novel agent CPX-351 in acute myeloid leukemia subgroups.

Data from a prospective pilot trial presented at the 2021 Transplantation and Cellular Therapy Meetings show that a maximum dose of 10 mg of ruxolitinib given peri-transplant is a safe and feasible treatment for patients with myelofibrosis.

Michael Bishop, MD, discusses the impact of chimeric antigen receptor T cell therapy across hematologic malignancies.

Treatment with axicabtagene ciloleucel is less likely to induce responses in patients with refractory large B-cell lymphoma who have never achieved a complete response to any line of prior therapy, according to findings from a single-center retrospective analysis.

Ruxolitinib was found to be safe for utilization in children after a pediatric dosing algorithm was tested in patients with chronic graft-versus-host disease and induced responses.

A phase 1 study is the first to demonstrate that JSP191 is safe and effective in older patients with MRD-positive acute myeloid leukemia or myelodysplastic syndrome who are undergoing nonmyeloablative allogeneic hematopoietic cell transplantation.

In a pivotal phase 2 trial, administration of narsoplimab to patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy led to impressive responses and a favorable survival benefit.

A post-hoc analysis of the practice-changing TRANSCEND NHL 001 trial revealed that exposure to anti-CD19 therapy in patients with relapsed/refractory large B-cell lymphoma, did not impact response to lisocabtagene maraleucel.

Finding presented on patients with hematologic malignancies at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR show that patients who had undergone a hematopoietic stem cell transplantation can accumulate effective immunity against SARS-CoV2 infection and non-SARS human coronaviruses.

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.

The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.

In the phase 3 VISION study, treatment with the MET inhibitor, tepotinib showed durable clinical activity as treatment of patients with MET exon 14 skipping non‒small cell lung cancer.

Patritumab deruxtecan demonstrated early and clinically meaningful activity in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer in the results of a phase 1 trial that were presented during the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore.